SCHEMBL6679666

SCHEMBL6679666

CCNC(=O)Nc1ccc(Cn2c(=O)c3c(n(C)c2=O)NC=C(C(=O)O)S3(=O)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTHFD2 P13995 1/20 0.38
MAPT P10636 3/20 0.33
ALDH1A1 P00352 3/20 0.33
ABCB1 P08183 1/20 0.33
HDAC1 Q13547 1/20 0.33
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
PARG Q86W56 2/20 0.32
PKM P14618 1/20 0.32
DOT1L Q8TEK3 1/20 0.32
USP1 O94782 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32
P2RX3 P56373 1/20 0.32
MMP13 P45452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7058428 0.83 SMN1; SMN2 (0.44) MAPTALDH1A1RAB9APOLBPKM
SCHEMBL7062549 0.80 ALDH1A1 (0.40) MTHFD2MAPTALDH1A1ABCB1HDAC1
SCHEMBL6678863 0.79 MTHFD2 (0.39) MTHFD2MAPTALDH1A1ABCB1HDAC1
SCHEMBL7121978 0.74 TRPA1 (0.50) MAPTALDH1A1LMNAKDM4E
SCHEMBL6681175 0.73 ALDH1A1 (0.41) MTHFD2MAPTALDH1A1ABCB1HDAC1
SCHEMBL7058877 0.71 ALDH1A1 (0.39) MTHFD2MAPTALDH1A1ABCB1HDAC1
SCHEMBL7062180 0.70 MTHFD2 (0.39) MTHFD2MAPTABCB1HDAC1RAB9A
SCHEMBL7114826 0.70 TRPA1 (0.40) ALDH1A1LMNAKDM4E
SCHEMBL6684000 0.64 ABCB1 (0.35) MTHFD2MAPTALDH1A1ABCB1RAB9A
SCHEMBL6677757 0.63 ABCB1 (0.37) MTHFD2MAPTALDH1A1ABCB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 MTHFD2 551/4885MAPT 1473/4885ALDH1A1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.